Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bone sarcomas are malignant tumors of mesenchymal origin. Complete surgical resection is the cornerstone of multidisciplinary treatment. However, advanced, unresectable forms remain incurable. A crucial step towards addressing this challenge involves comprehending the molecular mechanisms underpinning tumor progression and metastasis, laying the groundwork for innovative precision medicine-based interventions. We previously showed that tyrosine kinase receptor Ephrin Type-A Receptor 2 (EphA2) is overexpressed in bone sarcomas. EphA2 is a key oncofetal protein implicated in metastasis, self-renewal, and chemoresistance. Molecular, genetic, biochemical, and pharmacological approaches have been developed to target EphA2 and its signaling pathway aiming to interfere with its tumor-promoting effects or as a carrier for drug delivery. This review synthesizes the main functions of EphA2 and their relevance in bone sarcomas, providing strategies devised to leverage this receptor for diagnostic and therapeutic purposes, with a focus on its applicability in the three most common bone sarcoma histotypes: osteosarcoma, chondrosarcoma, and Ewing sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382444 | PMC |
| http://dx.doi.org/10.1186/s12964-024-01811-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating the mechanisms of indocyanine green tumour uptake in sarcoma cell lines and ex vivo human tissue.
J Pathol
September 2025
The North of England Bone and Soft Tissue Tumour Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Indocyanine green (ICG) is a well-established near-infrared dye which has been used clinically for several decades. Recently, it has been utilised for fluorescence-guided surgery in a range of solid cancer types, including sarcoma, with the aim of reducing the positive margin rate. The increased uptake and retention of ICG within tumours, compared with normal tissue, gives surgeons a visual reference to aid resection when viewed through a near-infrared camera.
View Article and Find Full Text PDFImmunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment.
J Immunother Precis Oncol
August 2025
Department of Medicine, Sylvester Comprehensive Cancer Center/University of Miami, Miami, FL, USA.
The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to date assessing the effectiveness of combined multitargeted vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors with immune checkpoint inhibitors (ICIs) in sarcoma. It is difficult to draw conclusions owing to limited data and primarily single-arm studies, although initial literature appears promising and requires further study.
View Article and Find Full Text PDFExploring the Utility of FDG PET-CT in Metastatic Recurrent Extra Skeletal Renal Osteosarcoma.
Indian J Nucl Med
August 2025
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Metastatic renal osteosarcoma is a rare entity. We report a case of a 52-year-old male postright nephrectomy status presented to us with metastatic renal osteosarcoma. 18-fluorine- fluorodeoxyglucose (F-FDG) avid lesions were seen in the right renal bed with extension to adjacent hepatic parenchyma.
View Article and Find Full Text PDFMolecular Morphology of Telangiectatic Osteosarcoma Associated With Сystic Content: A Case Report.
Cureus
August 2025
Histology and Embryology, David Tvildiani Medical University, Tbilisi, GEO.
This case report is focused on a patient (a 32-year-old previously healthy man) with a femoral bone tissue tumor. The case underscores the diagnostic complexity of Telangiectatic Osteosarcoma (TOS) with Aneurysmal Bone Cystic (ABC) lesion and the importance of maintaining special immunohistochemical markers for differential diagnosis between low-grade osteosarcoma, primary ABC, and suspected TOS, which is a true mimicker of ABC. On the other hand, this presentation describes some molecular rearrangements seen in ABC.
View Article and Find Full Text PDFHigh Levels of Systemic Inflammatory Markers Associated with Metastasis Incidence in Osteosarcoma.
Rev Bras Ortop (Sao Paulo)
June 2025
Department of Orthopedics and Traumatology, Faculty of Medicine, Udayana University, Prof. Ngoerah General Hospital, Bali, Indonesia.
Objective: The present study explores the association between these inflammatory markers and metastasis in osteosarcoma patients.
Methods: We conducted a retrospective analysis of osteosarcoma patients at our center between January 2022 and August 2024. We collected the clinical and laboratory data of the patients, including white blood cell differential count, C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), neutrophil-to-lymphocyte ratio (NLR), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels.